Video: Armed With Promising Clinical Data, Abivax Seeks Partners
This article was originally published in The Pink Sheet Daily
Executive Summary
Abivax CEO details plans to develop and commercialize late-stage anti-HIV and hepatitis B compounds, in a video interview.
You may also be interested in...
While Opening Dietary Ingredient Portfolio Wider, DuPont Opens Door On Online Supply Store
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: